Hidetomo Iwano

Dr. Hidetomo Iwano

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Environmental Health Perspectives
Verified
Journal Article
Open access
MNMiyu Nishikawa
Miyu Nishikawa
HIHidetomo Iwano
Hidetomo Iwano
RYRisa Yanagisawa
Risa Yanagisawa
NKNanako Koike
Nanako Koike
HIHiroki Inoue
Hiroki Inoue
HYHiroshi Yokota
Hiroshi Yokota
A peer-reviewed open access journal published by the National Institute of Environmental Health Sciences

Verified
Journal Article
Open access
PDF file
JFJumpei Fujiki
Jumpei Fujiki
KNKeisuke Nakamura
Keisuke Nakamura
TNTomohiro Nakamura
Tomohiro Nakamura
HIHidetomo Iwano
Hidetomo Iwano
In recent decades, phage therapy has been overshadowed by the widespread use of antibiotics in Western countries. However, it has been revitalized as a powerful approach due to the increasing prevalence of antimicrobial-resistant bacteria. Although bacterial resistance to phages has been reported in clinical cases, recent studies on the fitness trade-offs between phage and antibiotic resistance have revealed new avenues in the field of phage therapy. This strategy aims to restore the antibiotic susceptibility of antimicrobial-resistant bacteria, even if phage-resistant variants develop. Here, we summarize the basic virological properties of phages and their applications within the context of antimicrobial resistance. In addition, we review the occurrence of phage resistance in clinical cases, and examine fitness trade-offs between phage and antibiotic sensitivity, exploring the potential of an evolutionary fitness cost as a countermeasure against phage resistance in therapy. Finally, we discuss future strategies and directions for phage-based therapy from the aspect of fitness trade-offs. This approach is expected to provide robust options when combined with antibiotics in this era of phage ‘re’-discovery.

1 September 2016 in Applied and Environmental Microbiology
Verified
Journal Article
Closed access
PDF file
TFTakaaki Furusawa
Takaaki Furusawa
HIHidetomo Iwano
Hidetomo Iwano
YHYutaro Hiyashimizu
Yutaro Hiyashimizu
KMKazuki Matsubara
Kazuki Matsubara
HHHidetoshi Higuchi
Hidetoshi Higuchi
YTYutaka Tamura
Yutaka Tamura
Bacterial keratitis of the horse is mainly caused by staphylococci, streptococci, and pseudomonads. Of these bacteria,Pseudomonas aeruginosasometimes causes rapid corneal corruption and, in some cases, blindness. Antimicrobial resistance can make treatment very difficult. Therefore, new strategies to control bacterial infection are required. A bacteriophage (phage) is a virus that specifically infects and kills bacteria. Since phage often can lyse antibiotic-resistant bacteria because the killing mechanism is different, we examined the use of phage to treat horse bacterial keratitis. We isolatedMyoviridaeorPodoviridaephages, which together have a broad host range. They adsorb efficiently to host bacteria; more than 80% of the ΦR18 phage were adsorbed to host cells after 30 s. In our keratitis mouse model, the administration of phage within 3 h also could kill bacteria and suppress keratitis. A phage multiplicity of infection of 100 times the host bacterial number could kill host bacteria effectively. A cocktail of two phages suppressed bacteria in the keratitis model mouse. These data demonstrated that the phages in this study could completely prevent the keratitis caused byP. aeruginosain a keratitis mouse model. Furthermore, these results suggest that phage may be a more effective prophylaxis for horse keratitis than the current preventive use of antibiotics. Such treatment may reduce the use of antibiotics and therefore antibiotic resistance. Further studies are required to assess phage therapy as a candidate for treatment of horse keratitis.IMPORTANCEAntibiotic-resistant bacteria are emerging all over the world. Bacteriophages have great potential for resolution of this problem. A bacteriophage, or phage, is a virus that infects bacteria specifically. As a novel therapeutic strategy against racehorse keratitis caused byPseudomonas aeruginosa, we propose the application of phages for treatment. Phages isolated in this work hadin vitroeffectiveness for a broad range ofP. aeruginosastrains. Indeed, a great reduction of bacterial proliferation was shown in phage therapy for mouse models ofP. aeruginosakeratitis. Therefore, to reduce antibiotic usage, phage therapy should be investigated and developed further.

1 January 2017 in Journal of Veterinary Medical Science
Verified
Journal Article
Open access
PDF file
NONaoko Ohtani
Naoko Ohtani
HIHidetomo Iwano
Hidetomo Iwano
KSKoshi Suda
Koshi Suda
ETErika Tsuji
Erika Tsuji
KTKentaro Tanemura
Kentaro Tanemura
HYHiroshi Yokota
Hiroshi Yokota
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

9 January 2018 in Biology
Verified
Journal Article
Open access
PDF file
HIHidetomo Iwano
Hidetomo Iwano
YIYusuke Inoue
Yusuke Inoue
TTTakuji Takasago
Takuji Takasago
HKHironori Kobayashi
Hironori Kobayashi
TFTakaaki Furusawa
Takaaki Furusawa
YTYutaka Tamura
Yutaka Tamura
Bovine mastitis is an inflammation of the mammary gland caused by bacterial infection in dairy cattle. It is the most costly disease in the dairy industry because of the high use of antibiotics. Staphylococcus aureus is one of the major causative agents of bovine mastitis and antimicrobial resistance. Therefore, new strategies to control bacterial infection are required in the dairy industry. One potential strategy is bacteriophage (phage) therapy. In the present study, we examined the host range of previously isolated S. aureus phages ΦSA012 and ΦSA039 against S. aureus strains isolated from mastitic cows. These phages could kill all S. aureus (93 strains from 40 genotypes) and methicillin-resistant S. aureus (six strains from six genotypes) strains tested. Using a mouse mastitis model, we demonstrated that ΦSA012 reduced proliferation of S. aureus and inflammation in the mammary gland. Furthermore, intravenous or intraperitoneal phage administration reduced proliferation of S. aureus in the mammary glands. These results suggest that broad host range phages ΦSA012 is potential antibacterial agents for dairy production medicine.

1 February 2017 in Veterinary Microbiology
Verified
Journal Article
Closed access
SGSatoshi Gondaira
Satoshi Gondaira
HHHidetoshi Higuchi
Hidetoshi Higuchi
KNKoji Nishi
Koji Nishi
HIHidetomo Iwano
Hidetomo Iwano
HNHajime Nagahata
Hajime Nagahata